Their mechanism of action involves inhibiting cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed cell death 1 (PD-1) on T-cells, or its ligand (PDL-1), leading to enhanced T-cell activation and immune activity against cancer cells. This evidence concerns the gene CTLA4 and cancer.